Literatura

  1. Sikorska H, Cianciara J, Wiercińska–Drapało A.
    Fizjologiczne funkcje L–ornityny i L–asparaginianu oraz zasadność stosowania asparaginianu ornityny w wybranych stanach chorobowych. Pol Merkur Lekarski. 2010;28(168):490–495.

  2. Hartleb M, Simon K, Lipiński M, Drobnik J, Woroń J, Rydzewska G, Mastalerz–Migas A.
    Rekomendacje postępowania u chorych z zaburzeniami czynności wątroby i kamicą dróg żółciowych dla lekarzy POZ. Lekarz POZ. 2017;3(4):225–248.

  3.  Butterworth RF, Canbay A.
    Hepatoprotection by L–Ornithine L–Aspartate in Non–Alcoholic Fatty Liver Disease. Dig Dis. 2019;37(1):63–68. (online 2018).

  4. Canbay A, Sowa J–P.
    L–Ornithine L–Aspartate (LOLA) as a Novel Approach for Therapy of Non–Alcoholic Fatty Liver Disease. Drugs. 2019;79(Suppl 1):39–44.

  5. Butterworth RF, Kircheis G, Hilger N, McPhail MJW.
    Efficacy of L–Ornithine L–Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta–analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018;8(3):301–313.

  6. Butterworth RF, McPhail MJW.
    L–Ornithine L–Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta–Analyses. Drugs. 2019;79(Suppl 1):31–37.

  7. Butterworth RF.
    Beneficial effects of L–ornithine L–aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: systematic review with meta–analysis. Metab Brain Dis. 2020;35:75–81.

  8. Butterworth RF.
    L–Ornithine L–Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. Can J Gastroenterol Hepatol. 2019;2019:8182195.

  9. Kircheis G, Lüth S.
    Pharmacokinetic and Pharmacodynamic Properties of L–Ornithine L–Aspartate (LOLA) in Hepatic Encephalopathy. Drugs. 2019;79(Suppl 1):23–29.

  10. Kircheis G, Wettstein M, vom Dahl S, Häussinger D.
    Clinical Efficacy of L–Ornithine–L–Aspartate in the Management of Hepatic Encephalopathy. Metab Brain Dis. 2002;17(4):453–462.

  11. Kircheis G.
    Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L–ornithine–L–aspartate in the management of HE. Metab Brain Dis. 2016;31(6):1365–1367.

  12. He Q, Mao C, Chen Z, Zeng Y, Deng Y, Hu R.
    Efficacy of L–ornithine L–aspartate for minimal hepatic encephalopathy in cirrhosis: A meta–analysis of randomized controlled trials. Arab J Gastroenterol. 2024;25(2):84–92.

  13. Jhajharia A, Singh S, Jana S, Ashdhir P, Nijhawan S.
    Intravenous versus oral L–ornithine–L–aspartate in overt hepatic encephalopathy: a randomized comparative study. Sci Rep. 2024;14:11862.

  14. Horvath A, Traub J, Aliwa B, Bourgeois B, Madl T, Stadlbauer V.
    Oral intake of L–ornithine–L–aspartate is associated with distinct microbiome and metabolome changes in cirrhosis. Nutrients. 2022;14(4):748.

  15. Das A, Fröhlich D, Achanta L, Rowlands B, Housley G, Klugmann M, et al.
    L–Aspartate, L–Ornithine and L–Ornithine–L–Aspartate (LOLA) and Their Impact on Brain Energy Metabolism. Neurochem Res. 2020;45(6):1438–1450.

  16. Najmi AK, Pillai KK, Pal SN, Aqil M, Sharma M.
    Effect of L–ornithine L–aspartate against thioacetamide–induced hepatic damage in rats. Indian J Pharmacol. 2010;42(6):384–387.

  17. Ijaz S, Yang W, Winslet MC, Seifalian AM.
    The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis. Microvasc Res. 2005;70(3):129–137.